Despite the lack of a randomized controlled trial for the US WorldMeds’ investigational drug, an FDA advisory committee found that the company provided adequate data to support its benefit in high-risk neuroblastoma.
First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines
Total Worldwide Sales Were $14.5 Billion, a Decrease of 9%. | April 27, 2023